Abstract 2784 Development of Novel Sigma-2 Receptor Inhibitors: An in vitro and in silico study

The sigma-2 receptor (S2R, encoded by TMEM97) is a transmembrane protein that has emerged as a promising target for therapeutic intervention in various disease areas, including cancer biomarker detection, neurodegenerative disorders, and neuropathic pain. Additionally, sigma-2 receptors are implicated in critical cellular functions such as cell proliferation, immune modulation, and ion channel regulation. To address the unmet medical need, we designed and synthesized a novel class of benzodiazepines that selectively target the σ2 receptor without binding to GABA(A) receptors.